Highlight
1. Upadacitinib 15 mg daily plus a 26-week glucocorticoid taper significantly improves sustained remission rates in patients with giant-cell arteritis (GCA) compared to placebo with a 52-week taper.
2. Upadacitinib 7.5 mg does not demonstrate superior efficacy over placebo.
3. Safety profiles of upadacitinib and placebo are comparable over 52 weeks, with no major cardiovascular events observed.
4. Real-world evidence supports the potential effectiveness of Janus kinase inhibitors (JAKi), including baricitinib, tofacitinib, and upadacitinib, in relapsing GCA, even in patients failing prior immunosuppressants and biologics.
